431 related articles for article (PubMed ID: 22034206)
1. Clinical trials in the era of personalized oncology.
Maitland ML; Schilsky RL
CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
[TBL] [Abstract][Full Text] [Related]
2. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
Golan T; Milella M; Ackerstein A; Berger R
J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
[TBL] [Abstract][Full Text] [Related]
3. Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA.
Burstein HJ
Expert Rev Anticancer Ther; 2005 Aug; 5(4):581-3. PubMed ID: 16111459
[No Abstract] [Full Text] [Related]
4. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic breast cancer: looking towards the future.
Amar S; Roy V; Perez EA
Breast Cancer Res Treat; 2009 Apr; 114(3):413-22. PubMed ID: 18465221
[TBL] [Abstract][Full Text] [Related]
6. [Requirements for the development of molecularly defined targeted therapy in oncology].
Schultze JL
Med Klin (Munich); 2006 Aug; 101(8):617-23. PubMed ID: 16896568
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer subtypes: morphologic and biologic characterization.
Masood S
Womens Health (Lond); 2016 Jan; 12(1):103-19. PubMed ID: 26756229
[TBL] [Abstract][Full Text] [Related]
8. Cancer genomics and clinical practice: how can we close the gap more quickly?
Konecny GE
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):1-3. PubMed ID: 27941363
[No Abstract] [Full Text] [Related]
9. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
10. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
11. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
Fornier M; Esteva FJ; Seidman AD
Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
[TBL] [Abstract][Full Text] [Related]
13. Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research.
Syme R; Carleton B; Leyens L; Richer E
Public Health Genomics; 2015; 18(6):372-80. PubMed ID: 26565702
[TBL] [Abstract][Full Text] [Related]
14. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
[TBL] [Abstract][Full Text] [Related]
15. Role of Herceptin in primary breast cancer: views from North America and Europe.
Leyland-Jones B; Smith I
Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
[TBL] [Abstract][Full Text] [Related]
16. Next steps in clinical trial redesign.
Nicholas J
J Natl Cancer Inst; 2012 Jan; 104(2):90-2. PubMed ID: 22215851
[No Abstract] [Full Text] [Related]
17. Translational research in breast cancer.
Toi M; Takebayashi Y; Chow LW
Breast Cancer; 2005; 12(2):86-90. PubMed ID: 15858437
[TBL] [Abstract][Full Text] [Related]
18. Functional MR Imaging Techniques in Oncology in the Era of Personalized Medicine.
Benz MR; Vargas HA; Sala E
Magn Reson Imaging Clin N Am; 2016 Feb; 24(1):1-10. PubMed ID: 26613872
[TBL] [Abstract][Full Text] [Related]
19. Personalized medicine in oncology: next generation.
Chiang A; Million RP
Nat Rev Drug Discov; 2011 Dec; 10(12):895-6. PubMed ID: 22129983
[No Abstract] [Full Text] [Related]
20. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
